TheProfitWatch

DNTH - Dianthus Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
39.82 2.07 (5.2%) 0.13 (0.32%) 0.13 (0.31%) -0.27 (-0.64%) 0.18 (0.45%) 1.5 (3.71%) --- 0.18 (0.45%)

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.88
Diluted EPS:
-0.88
Basic P/E:
-47.6023
Diluted P/E:
-47.6023
RSI(14) 1m:
60.38
VWAP:
41.76
RVol:

Events

Period Kind Movement Occurred At

Related News